# Justice Sachin Datta

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/justice-sachin-datta
Canonical HTML page: https://getyourbrief.com/entity/justice-sachin-datta

## Timeline

- **2026-04-15**: Expected Response — Deadline for CDSCO to justify the delay in regulatory action (Estimated).
- **2026-03-17**: Contempt Petition Filed — Petitioners allege CDSCO failed to act on the court's previous safety mandate.
- **2026-03-17**: Notice Issued — Justice Sachin Datta issues formal contempt notice seeking a response from the CDSCO.
- **2026-03-17**: Contempt Notice Issued — Justice Sachin Datta issues formal notice to CDSCO seeking an explanation for the delay.
- **2026-03-17**: Contempt Petition Filed — Petitioners allege CDSCO failed to act on the court's previous directions.
- **2026-03-17**: Contempt Notice Issued — Justice Sachin Datta seeks a formal response from CDSCO regarding the delay.
- **2026-03**: Original Court Order — Delhi HC directs CDSCO to examine safety and regulatory concerns of diabetes drugs used for weight management.
- **2026-02**: Contempt Petition Filed — Petitioners move court alleging CDSCO failed to meet the review deadline.
- **2025-Q4**: Initial Judicial Order — Delhi HC directs CDSCO to examine the safety of diabetes drugs used for weight management.
- **2025-Q3**: Initial Court Order — Delhi HC directs CDSCO to evaluate safety of diabetes drugs for weight loss.

## Recent coverage (3 stories, network-wide)

### Delhi High Court Issues Contempt Notice to CDSCO Over Weight-Loss Drug Oversight
2026-03-18 00:53:29 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 2

The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to examine safety concerns regarding the off-label use of diabetes medications for weight loss. This judicial escalation highlights growing concerns over the unregulated boom of GLP-1 agonists in the Indian market.
Full story: https://getbiobrief.com/story/delhi-hc-contempt-notice-cdsco-diabetes-weight-loss

### Delhi High Court Issues Contempt Notice to CDSCO Over Weight-Loss Drug Delay
2026-03-18 00:52:56 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2

The Delhi High Court has issued a contempt notice to India's drug regulator, CDSCO, for failing to comply with judicial orders to evaluate the safety of diabetes drugs used off-label for weight loss. This escalation signals a growing legal intolerance for regulatory delays amidst a global surge in GLP-1 receptor agonist demand.
Full story: https://gethealthbrief.com/story/delhi-hc-contempt-notice-cdsco-diabetes-weight-loss

### Delhi HC Issues Contempt Notice to CDSCO Over Weight-Loss Drug Regulation Delay
2026-03-18 00:48:01 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2

The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to act on a judicial mandate to evaluate the safety of diabetes medications used off-label for weight loss. This escalation highlights growing judicial impatience with regulatory inertia regarding the global surge in GLP-1 receptor agonist use.
Full story: https://getlegalbrief.com/story/delhi-hc-contempt-notice-cdsco-diabetes-weight-loss

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.